Nanomaterials in gene therapy and genome editing: challenges and emerging directions Authors: Mingyang Jiang, Ke Zhang, Zheng Wang, Ming Gao, Shanggui Su, Junjun He, Huihui Xu, Zhandong Bo, Zhenqi Jiang, Chengcheng Zhang, James HP Hui, Ruqiong Wei Published: 2025 ABSTRACT AbstractNanomaterials are redefining the landscape of gene and genome editing, yet their translation to clinical reality remains constrained by multiple unresolved challenges. While they provide structural and functional advantages for delivering nucleic acids and CRISPR/Cas systems across biological barriers, their behavior within living systems is often unpredictable, leading to issues such as off-target editing, immune activation, and inconsistent biodistribution. The design of nanocarriers, whether lipid-based, polymeric, inorganic, must therefore balance efficiency with safety, integrating physicochemical precision with biological adaptability. Recent advances in ionizable lipid nanoparticles demonstrate how fine-tuning charge, surface chemistry, and degradation kinetics can enhance endosomal escape and target specificity, but reproducibility and large-scale manufacturing continue to limit broader application. Moreover, polymeric and exosome-inspired systems promise modularity and targeted reuse, yet they demand clearer understanding of long-term biocompatibility and regulatory acceptance. The future of nanomaterial-enabled genome engineering depends not only on optimizing delivery vehicles but also on establishing predictive models of nano–bio interactions, harmonizing ethical oversight, and developing standardized evaluation pipelines that link nanoscale design to therapeutic outcomes.Graphical Abstract Keywords: Lipid nanoparticles, Polymeric nanoparticles, CRISPR–Cas delivery, Genome editing in vivo, Targeted gene delivery, Endosomal escape, Off-target mitigation, Regulatory considerations Introduction Gene therapy involves treating or preventing disease by introducing or altering genetic material (DNA or RNA) in a patient’s cells. Traditionally, viral vectors (engineered viruses) were used to deliver therapeutic genes because viruses are naturally good at infecting cells and inserting genetic material [1]. Early gene therapy trials often used retroviruses, adenoviruses, or related vectors, which achieved high gene transfer efficiency. However, viral vectors raised safety concerns: they can trigger unwanted immune reactions and sometimes integrate their genes in harmful ways (causing insertional mutations) [2]. They also have practical limits, such as only fitting small genes and being difficult to manufacture for repeated dosing. Due to these limitations, researchers began shifting toward non-viral delivery systems for gene therapy. Non-viral approaches (for example, using plasmid DNA or nanoparticles) tend to be less immunogenic and can carry larger genetic payloads, making them attractive alternatives [3–5]. In parallel with advances in delivery methods, there have been major breakthroughs in genome editing technologies. Traditional gene therapy usually adds a working gene into cells, whereas genome editing directly fixes or alters the DNA in place. Early programmable nucleases like zinc-finger nucleases (ZFNs) and TALENs demonstrated that it was possible to cut DNA at specific sites to correct genetic errors [6–9]. These tools, invented in the 1990 s and 2000 s, paved the way but were complex to design for each new target. The rise of CRISPR–Cas systems in the early 2010 s revolutionized genome editing by making it much simpler and more precise to target genes. CRISPR–Cas9, in particular, uses an RNA guide to find the DNA sequence of interest, which is easier to program than engineering new proteins for each target as required with ZFNs or TALENs [10]. Since its introduction in 2012, CRISPR–Cas9 has quickly become the most widely used gene-editing tool. It enables researchers to cut DNA and introduce changes (such as inserting or deleting sequences) with high precision [11]. Notably, CRISPR-based gene editing has already entered clinical trials for instance, to edit immune cells in cancer therapy, highlighting its significant potential in gene therapy [12]. The development of these programmable nucleases has expanded what gene therapy can achieve, moving the field from just adding genes toward directly rewriting faulty genes [13]. Alongside new genes and editing tools, the vehicles that carry these therapies into cells have evolved. Nanomaterials have emerged as key players in modern gene delivery, especially for non-viral systems [14]. These carriers are extremely small (on the scale of nanometers), which offers several advantages [15]. At this scale, delivery particles can enter tissues and cells more easily and can be engineered to avoid detection by the immune system. They also protect genetic cargo (DNA, RNA, or protein complexes) from being degraded in the body, ensuring that more of the therapeutic material reaches the target cells [16]. Moreover, nanomaterial-based vectors tend to cause fewer immune reactions than viruses and can often be produced in a more straightforward, scalable way. Because their properties can be finely tuned (for example, by modifying surface chemistry or size), they provide a versatile platform to improve the safety and efficiency of gene delivery [17, 18]. The aim of this review is to critically examine the current landscape of gene delivery in the context of gene therapy and genome editing, and to highlight both the obstacles and emerging solutions in the field. We provide an overview of the latest non-viral delivery techniques with an emphasis on nanomaterial-based carriers and discuss how they are addressing the limitations of earlier methods. This includes surveying recent developments (for instance, improvements in nanoparticle design and novel genome editing platforms) and evaluating ongoing progress in preclinical studies and clinical trials. By summarizing these advances and the remaining gaps, the review intends to guide future research efforts towards the most pressing problems. Ultimately, understanding the current challenges and opportunities will help researchers and clinicians chart a path forward for translating gene therapies and genome editing technologies into safe and effective clinical treatments. Nanomaterial properties and functionalities Engineered nanomaterials are very important in improving disease diagnosis and treatment, as they help to solve the problems of traditional drug delivery methods [14]. Nanotechnology gives new solutions such as targeting specific cells and transporting molecules to certain organelles [12]. This progress makes drug delivery more accurate and helps to overcome issues like biodistribution and intracellular movement [19]. In 2000, the US National Science and Technology Council launched the National Nanotechnology Initiative (NNI), which introduced key plans and challenges to encourage development in this area and support the growth of advanced nano-enabled technologies [20]. NPs show great potential because they improve the stability and solubility of cargos, help with transport across membranes, and increase circulation times. These features make treatments safer and more effective (Fig. 1). However, even with much research, there is still a gap between results in animal studies and human applications, mainly because of limited knowledge about the differences in physiology and disease conditions [21]. Schematic representation of the multifaceted roles of nanoparticles in cancer applications. Nanoparticles exhibit therapeutic, diagnostic, biological, and immunomodulatory effects, influencing tumor progression through mechanisms such as targeted drug and gene delivery, enhanced imaging, modulation of the tumor microenvironment, and immune response regulation. Both beneficial (anticancer) and paradoxical (protumor) effects may occur depending on nanoparticle composition, dose, and physicochemical properties Lipid-based vectors, composed of fat-like molecules arranged into liposomes or lipid nanoparticles (LNPs), have become one of the most successful gene delivery platforms. Their amphiphilic nature allows them to encapsulate DNA or RNA and merge with cell membranes, enabling efficient intracellular cargo release. Owing to their high biocompatibility and delivery efficiency, lipid nanoparticles have achieved remarkable success in medical applications, notably in the development of mRNA-based vaccines. These systems demonstrate how fine-tuning lipid composition and structure can dramatically enhance gene transfer, paving the way for broader use in gene therapy and genome editing. Polymeric vectors, on the other hand, rely on synthetic or natural polymers such as polyethyleneimine (PEI) or dendrimers to form complexes with nucleic acids. Their positive charges bind the negatively charged DNA or RNA, condensing them into nanoscale assemblies suitable for cellular uptake. The flexibility of polymeric nanocarriers lies in their tunability—researchers can tailor parameters such as size, charge, and surface chemistry to optimize delivery and release kinetics. Furthermore, polymers can be engineered with targeting ligands or stimuli-responsive groups, improving selectivity and control over gene expression. Their chemical stability and ease of modification make them appealing candidates for sustained and targeted delivery in therapeutic contexts. Inorganic nanoparticles, including those composed of gold, silica, or iron oxides, bring unique structural and physicochemical advantages to gene delivery. Their rigidity and defined morphologies enable precise control over particle size and surface functionality [15]. DNA or RNA can be adsorbed or covalently attached to their surfaces, while hybrid systems—combining inorganic cores with organic coatings—enhance their compatibility with biological systems. Gold nanoparticles, for example, have shown promise in binding nucleic acids and releasing them within target cells [16]. Collectively, these nanocarriers—lipidic, polymeric, and inorganic—are being refined to overcome key delivery barriers in gene therapy. By designing carriers that direct their genetic payloads to specific cells and release them in a controlled manner, scientists are advancing the safe and efficient application of genetic medicines and CRISPR-based genome editing [20]. Closing this gap is very important to achieve the full clinical benefits of nanomedicines [22–25]. In gene therapy, nanoparticles are deliberately engineered so that their surfaces carry specific ligands (such as peptides, antibodies, or sugars) which recognize markers on target cells [26]. Attaching these ligands “paints” the particle surface, allowing the nanocarrier to bind only to cells that display the matching receptor. This active targeting strategy ensures that therapeutic genes are delivered into the intended cells (for example, cancer cells overexpressing a certain receptor) rather than being taken up by healthy cells. By matching high-affinity ligands to receptors that are abundant on target tissues, the functionalized nanoparticle navigates through complex biological fluids and binds tightly to the correct cell type [27–30]. This selective binding triggers receptor-mediated internalization of the nanoparticle into the cell, where the genetic cargo can be released. In effect, the custom surface ligands act like an address label, dramatically improving delivery efficiency and reducing side effects from non-specific uptake [31–35]. One of the toughest obstacles in gene therapy is the blood–brain barrier (BBB) – a tight endothelial barrier that protects the brain by blocking most large or charged molecules from entering from the blood. The BBB’s semipermeable membrane keeps out pathogens and toxins but also prevents most therapies from reaching the brain [36–38]. To overcome this, researchers functionalize nanoparticles with ligands that mimic the BBB’s natural transport pathways [39]. For example, nanoparticles can be decorated with transferrin, insulin, or apolipoprotein ligands that bind to receptors on brain capillary endothelium. Once bound, the nanoparticle–ligand complex is shuttled across the BBB via receptor-mediated transcytosis [40]. This means that by choosing the right ligand (one that matches an abundant BBB receptor), the nanocarrier can hitch a ride through the barrier and deliver genes into brain tissue [41]. In practice, scientists carefully engineer such ligands (or antibodies/peptides that target them) so that nanoparticles effectively “unlock” the BBB’s transport systems. Studies have shown that transferrin- or apolipoprotein-conjugated nanoparticles can reach intracerebral tumors or deliver drugs into the CNS, demonstrating how ligand design is crucial for brain targeting. In short, surface-functionalized ligands provide a route across biological barriers: by exploiting specific BBB receptors, the nanoparticles gain entry into the otherwise protected brain [42–48]. After administration, nanocarriers encounter immediate challenges posed by the immune system, which rapidly clears foreign materials from circulation. To overcome this, nanoparticles must exhibit “stealth” characteristics that enable them to circulate long enough to reach their intended targets [49]. The surface functionality of nanoparticles plays a crucial role in achieving this stealth effect. By coating the nanoparticle surface with biocompatible polymers or biomolecules, a protective shell is formed that prevents immune recognition and clearance [50]. One of the most common approaches is the addition of polyethylene glycol (PEG) chains to the nanoparticle surface, known as PEGylation. This hydrophilic polymer layer effectively conceals the particle from immune surveillance by masking it from plasma proteins and immune cells, significantly extending its blood circulation half-life. PEGylated nanoparticles, for instance, can persist in the bloodstream for hours rather than minutes because the flexible PEG chains create a steric barrier that inhibits the adsorption of opsonins—proteins that label foreign entities for clearance by macrophages [51]. In parallel, biomimetic strategies further enhance nanoparticle stealth by coating them with natural “self” materials, such as serum albumin or fragments of red blood cell membranes [52]. These biologically derived shells endow the nanoparticles with endogenous characteristics, allowing them to blend into the body’s biological environment and avoid detection by phagocytic cells [53]. Additionally, fine-tuning the surface charge of nanoparticles contributes to immune evasion. Maintaining a neutral or slightly negative surface minimizes nonspecific interactions with serum proteins and cell membranes, reducing opsonization and uptake by macrophages. In general, nanoparticles that are small, hydrophilic, and negatively charged exhibit reduced immune activation and improved systemic stability [53, 54]. Selecting the right ligand is fundamental for efficient gene delivery. First, researchers identify molecular markers or receptors that are highly expressed on the target cell’s surface. Common targets include receptors like integrins, transferrin receptor, folate receptor, or cell-specific antigens [32–38]. Next, a ligand (such as a peptide, antibody fragment, aptamer, or small molecule) is chosen with strong binding affinity for that receptor. Attaching this ligand to the nanoparticle surface creates a highly specific address label: the nanocarrier is “seen” preferentially by target cells. This selectivity serves two purposes [39]. First, it boosts cellular uptake: when the ligand binds its cognate receptor, it triggers receptor-mediated endocytosis, pulling the nanoparticle into the cell interior where gene cargo can be released [40]. For example, integrin-binding peptides (like RGD) cause nanocarriers to be engulfed by cancer cells that overexpress integrin receptors. Transferrin or antibodies against EGFR have similarly been used to shuttle genes into tumor cells. Second, specificity minimizes off-target effects: because the ligand does not bind receptors on healthy cells, the nanoparticle is far less likely to be taken up by non-target cells. In other words, ligand-receptor pairing sharpens the discrimination between diseased and normal tissues [51–55]. In practice, the ligand selection and conjugation process involves: (1) profiling the target cell surface to find overexpressed receptors; (2) choosing or engineering a ligand with high affinity for that receptor; (3) chemically attaching the ligand to the nanoparticle; and (4) testing uptake [42–46]. Successful binding of the ligand to its receptor then induces internalization of the nanoparticle, delivering the genetic payload inside the target cell. Because the process is so specific, any binding to unintended cells is greatly reduced, enhancing therapeutic efficacy and safety [52, 53]. Nanocomposite materials combine multiple components (metals, oxides, polymers, carbon materials, etc.) and can be prepared by chemical (sol–gel, co-precipitation, hydrothermal, sonochemical reduction) or biological/green methods (plant or microbial extracts as reducing/stabilizing agents) [54]. Chemical routes (e.g. aqueous reduction of Ag^ + with citrate or NaBH_4, or sol–gel formation of ZnO) typically yield narrowly sized, often citrate- or polymer-capped NPs, whereas green synthesis (e.g. Trillium or other plant extracts) produces biomolecule-capped NPs with variable shapes [55]. For example, Negi et al. used Trillium govanianum extract to reduce Ag^ + onto graphene oxide (GO), yielding a GO–Ag nanocomposite with uniformly dispersed Ag nanospheres (10–100 nm) on thin GO sheets. Similarly, sonochemical exfoliation of graphene oxide in the presence of Zn^2 + yields a reduced GO–ZnO composite with ZnO nanoparticles anchored on graphene. Nanocomposite morphology (spherical, rod-like, sheet) and size (often 5–100 nm) depend on the synthesis method and capping agents used. In green methods, residual plant biomolecules can cap and stabilize the NPs, influencing size and biocompatibility [56]. Silver nanoparticles (AgNPs) are widely used antimicrobials. AgNPs disrupt bacterial membranes by adsorbing onto the cell wall, creating pores/gaps and inducing membrane destabilization [57]. This membrane-piercing effect causes cytoplasmic leakage. Inside cells, AgNPs release Ag^ + ions that bind thiol groups, generating reactive oxygen species (ROS) and inactivating proteins, enzymes and DNA. Chitosan, a positively charged biopolymer, is often combined with AgNPs: its amino groups bind to bacterial cell walls (negatively charged), aiding adhesion, and it can form a matrix that releases Ag^ + gradually. For example, a chitosan–Ag nanocomposite (not explicitly cited above) exhibits dual action (chitosan disrupts membranes electrostatically, while Ag^ + kills internally). Silver-based nanocomposites often show broad-spectrum killing of Gram-negative and Gram-positive bacteria and fungi [58–60]. Graphene oxide (GO) and reduced graphene oxide (rGO) alone have only modest antimicrobial activity, but serve as excellent supports for metals. GO’s 2D sheets have sharp edges that physically cut or pierce microbial membranes [61]. When decorated with AgNPs (GO–Ag), the composite shows synergistic killing: Negi et al. reported that GO–Ag nanocomposites inhibited nosocomial pathogens (e.g. E. coli, S. aureus, C. albicans) much more effectively than AgNPs alone. In that green-synthesized GO–Ag, AgNPs (10–100 nm spheres) were evenly dispersed on thin GO sheets. The GO sheets both disrupt membranes (via sharp edges) and prevent AgNP agglomeration [62]. This stabilizes Ag^ + release and prolongs antimicrobial action. As a result, the MIC of GO–Ag was about half that of AgNP alone (i.e. only ~ 62.5–250 µg/mL GO–Ag vs 125–500 µg/mL AgNP). Biofilm assays showed ~ 80–96% inhibition of mixed bacterial–yeast biofilms by GO–Ag at sub-MICs. Impregnating catheters with GO–Ag nanocomposite prevented adhesion of P. aeruginosa and C. auris, whereas bare catheters were heavily colonized. Thus GO–Ag composites combine chemical (Ag^ + ROS) and physical (membrane rupture) mechanisms and exhibit potent broad-spectrum and anti-biofilm activity [63]. ZnO nanoparticles (often 20–100 nm) are another key antimicrobial agent. ZnO exerts multiple effects: direct contact with bacterial walls disrupts integrity, released Zn^2 + ions interfere with membrane proteins, and ZnO’s photocatalytic activity generates ROS (H_2O_2, •O_2^–) under light [64]. In fact, the antibacterial potency of ZnO increases sharply as particle size decreases. For example, in one review ZnO’s mechanisms were summarized as direct wall disruption, Zn^2 + release, and surface-mediated ROS formation. Zinc oxide can be combined with carbon or metal to boost activity [65–68]. A reduced GO–ZnO composite (synthesized sonochemically) showed higher antibacterial/biofouling efficacy against E. coli, S. marcescens and B. subtilis than either component alone. In that study, intracellular ROS measurements confirmed that the rGO–ZnO’s kill was dominated by ROS generation (Zn^2 + release was negligible). Importantly, ZnO composites tend to be less prone to agglomeration on graphene supports, providing sustained ROS output [69, 70]. Doping or combining Ag with ZnO often yields synergistic antimicrobials. A recent review reports that Ag/ZnO nanocomposites kill microbes via three concurrent mechanisms: (1) enhanced ROS formation (photocatalytic activity boosted by Ag); (2) release of Ag^ + and Zn^2 + ions; and (3) direct nanoparticle–cell contact [71, 72]. Various other nanocomposites (TiO₂–Ag, CuO–graphene, etc.) follow similar principles: metal ions and ROS from one component combined with physical damage or adsorption by another. Although not exhaustively cited here, a common theme is that composites often work via multiple complementary mechanisms [73]. For example, chitosan–ZnO or chitosan–CuO composites provide polymeric binding to membranes plus metal oxide toxicity. Many studies also report synergism with antibiotics: e.g. embedding AgNPs or ZnO into antibiotic-loaded materials can resensitize resistant bacteria by weakening their defense (noted in several reviews). The net effect in all cases is a dose-dependent enhancement: composites can often achieve ≥ 95% kill at moderate concentrations (tens of μg/mL), whereas individual components fail or require higher dose [74]. Nanocomposite materials are also applied in cancer therapy, usually by exploiting oxidative stress or targeted delivery. Many metal-oxide and metal NPs selectively kill cancer cells: for instance, ZnO NPs are much more toxic to cancer cells (by ~ 28–35 ×) than to normal cells. This selectivity arises in part because cancer cells tend to have more acidic microenvironments and less efficient antioxidant defenses (despite often upregulated glutathione). ZnO can thus generate intracellular ROS that induces apoptosis in tumor cells [75]. Graphene–metal hybrids have also been tested: e.g. GO–Ag composites (in addition to antibacterial uses) have been explored as photothermal or SERS-active anticancer agents (by absorbing NIR light and heating tumors, or by drug delivery). Magnetic nanocomposites (e.g. Fe_3O_4 core with polymer shell) can be directed by fields to tumors [76]. A key mechanism in nanomedicine is redox modulation. Cancer cells often overexpress glutathione (GSH) to neutralize ROS, making them resistant to ROS-generating treatments. Recent reviews emphasize designing “GSH-consuming” nanomedicines: certain metal or metal-oxide nanoparticles can catalytically deplete intracellular GSH [77]. For example, MnO_2 or Fe-based NPs can oxidize GSH to GSSG, lowering the cell’s antioxidant capacity. Liu et al. note that depleting GSH enhances the efficacy of ROS-based therapies. Thus, nanocomposites that combine ROS generation (from ZnO, TiO_2, Fe) with GSH exhaustion lead to synergistic tumor killing. In addition, targeted nanocomposites (e.g. antibody-conjugated gold nanoshells, or folate–polymer cores) deliver chemotherapeutics or siRNA specifically to cancer cells while minimizing systemic toxicity [78, 79]. Across antimicrobial and antitumor applications, several common mechanisms of action underlie the efficacy of nanomaterials. One major route involves membrane disruption, where sharp-edged or high-aspect-ratio nanostructures—such as graphene sheets, ZnO nanorods, or surfactant-removed TiO₂ nanospikes—physically penetrate cell walls, causing leakage of intracellular contents. Similarly, cationic nanoparticles like silver attach electrostatically to negatively charged membranes, inducing poration and structural collapse. Another dominant mechanism is reactive oxygen species (ROS) generation, driven by photocatalytic semiconductors (ZnO, TiO₂) and redox-active metals that produce •OH, H₂O₂, and •O₂⁻ radicals capable of oxidizing lipids, proteins, and DNA. Metal nanoparticles such as Ag and Cu can also catalyze ROS indirectly through Fenton-like reactions; for instance, rGO–ZnO composites primarily exert bactericidal effects via intracellular ROS overproduction, leading to lipid peroxidation and cell death [80]. Ionic toxicity further contributes, as metal dissolution releases ions like Ag⁺, Zn2⁺, and Cu2⁺ that bind to thiol groups or disrupt electron transport proteins, impairing essential enzymatic functions. The controlled release of these ions from nanocomposite matrices ensures prolonged antimicrobial activity. In many systems, synergistic interactions amplify these effects—such as in GO–Ag or Ag–ZnO composites, where physical membrane disruption by GO enhances Ag⁺ uptake, and Ag doping boosts ZnO’s ROS output. Such synergy not only heightens efficacy but also allows for reduced dosages, minimizing toxicity, and can enhance antibiotic effectiveness by destabilizing biofilms or cellular membranes. Antibiofilm activity is another crucial aspect, as nanocomposites inhibit biofilm establishment by destroying planktonic cells and disrupting extracellular polymeric substances (EPS); for example, GO–Ag coatings induce cell deformation and leakage in Pseudomonas aeruginosa, preventing biofilm development. Beyond microbial systems, in cancer therapy, nanocomposites can disrupt biochemical pathways by depleting intracellular glutathione (GSH), a key antioxidant. Metal nanoparticles oxidize GSH, collapsing the redox balance and sensitizing cancer cells to oxidative stress–induced apoptosis. Together, these multifaceted mechanisms—spanning physical, chemical, and biochemical interactions—underscore the broad-spectrum potency of nanomaterials against both microbial and cancerous targets [81–84]. Multifunctional nanocomposites are also engineered as gene delivery vectors (non-viral carriers for DNA/RNA). Here, physicochemical properties are critical: size, shape, surface charge, and biodegradability dictate delivery efficiency and safety. In general, small nanoparticles (< 100 nm) are taken up more readily by cells, and specific geometries (e.g. spherical vs rod-like) can influence endocytic pathways. Importantly, surface charge controls nucleic acid binding: a positive surface electrostatically complexes with negatively charged DNA/RNA, boosting loading capacity. For example, PEGylated cationic polymers or lipid coatings with positive headgroups can bind and condense plasmid DNA [85–87]. However, highly positive particles may also trigger toxicity or non-specific uptake; thus, many vectors are designed with modulated charge. Surface modification (e.g. PEGylation) imparts a neutral/hydrophilic “stealth” layer, reducing protein adsorption and immune clearance. PEG chains can also reduce cytotoxicity while retaining gene loading sites beneath. Balancing biodegradation is another challenge: biodegradable polymers (PLGA, chitosan) allow gradual release of the genetic cargo and breakdown into non-toxic byproducts, but if they degrade too slowly, cargo release and clearance are impeded; if too quickly, premature gene release or dose dumping can occur. In practice, composite vectors to solve this, researchers use stable and biocompatible materials, such as lipid-based nanoparticles or polymer carriers [86]. These materials protect the genetic cargo from enzymes, keeping it stable during circulation and helping deliver it to the right tissues, as shown in Fig. 2. Illustration of a nanoparticle for gene therapy. Reprinted from [87], with permission from Springer Nature Advances in gene-based therapies Nanomaterials can encapsulate therapeutic genes, protecting them from degradation and facilitating their controlled release [88]. Additionally, surface modifications of nanomaterials allow for improved cellular uptake and intracellular trafficking of therapeutic genes [89]. This targeted and controlled delivery helps optimize the therapeutic effect while minimizing potential side effects [90]. Moreover, nanomaterials can overcome physiological barriers, such as the blood–brain barrier, enabling the delivery of gene therapies to previously inaccessible tissues [91]. These advancements in delivery technology open up new possibilities for treating diseases with a genetic component that were previously challenging to address effectively [92]. One example of nanomaterial-enhanced gene therapy is the use of liposomal nanoparticles [93]. These lipid-based nanomaterials have demonstrated success in delivering therapeutic genes, especially for treating diseases like cancer [94]. Liposomal nanoparticles can encapsulate genes, protect them during circulation, and release them specifically at the target site, maximizing the therapeutic effect while minimizing damage to healthy tissues [95]. Multifunctional nanoparticles play a crucial role in preclinical gene delivery studies, offering a versatile platform for enhancing the efficiency and specificity of gene targeting [96]. One key strategy in nanoparticle functionalization involves PEGylation, employing entities such as PEG-βCD and PEG-PEI [97]. This approach contributes to enhanced stabilization, prevents unwanted protein absorption, and extends circulation time, thereby optimizing the overall performance of gene delivery systems [98]. Another significant aspect of multifunctional nanoparticles lies in their targeting capabilities [99]. Utilizing constructs like RGD-HA-PEI-PBLG, R-PEG20C, and transferrin-lipid, researchers have achieved improved gene target efficacy in vivo [100]. These targeted delivery systems enable a more precise and efficient approach, enhancing the therapeutic impact of gene delivery [101]. Stimulus-responsive nanoparticles further enhance gene delivery efficacy [102]. Through pH-sensitive, light-sensitive, and redox-sensitive designs, these nanoparticles respond dynamically to the microenvironment, ensuring optimal gene delivery under specific conditions [103]. This adaptability enhances the overall success of gene delivery systems in vivo [54]. Cell-penetrating nanoparticles, such as p(DAHa-E/APIb), exhibit the ability to cross cell membranes efficiently, facilitating enhanced cellular uptake [104]. This property is vital for ensuring effective delivery of genetic material into target cells, thereby maximizing the therapeutic potential of gene-based therapies [105]. In the context of endosome escaping, nanoparticles like (Arg)7-FI-PNA have demonstrated the ability to cross cell membranes and improve endosomal escaping, overcoming a significant barrier in the gene delivery process [106]. This capability is critical for ensuring that the genetic material reaches its intended destination within the cell [107]. Nuclear localization is another key consideration, and nanoparticles such as PC/pDNA/NLS and VKRKKKP-R8 have been designed to facilitate nuclear localization [108]. This capability ensures that the delivered genetic material reaches the cell nucleus, where it can exert its therapeutic effects more effectively [109]. Table 1 gives a detailed summary of gene-based therapies that use nanomaterials to treat different diseases. One clear example is the use of polymeric nanoparticles in delivering gene therapies for genetic disorders [110]. These nanoparticles, made of biocompatible and biodegradable materials, have been shown to deliver therapeutic genes effectively to target cells [111]. In Duchenne muscular dystrophy (DMD), a serious genetic disease, researchers have used polymeric nanoparticles to carry the dystrophin gene. This method restored gene expression and reduced disease symptoms in preclinical studies [112]. Another important example is the use of viral vectors covered with nanomaterials to improve their safety and efficiency [113]. Adeno-associated virus (AAV), which is often used in gene therapy, has been coated with nanomaterials to increase stability and improve targeting [114]. This improved AAV has shown good results in treating inherited retinal diseases by delivering therapeutic genes to the retina, slowing the loss of vision [115]. Lipid-based nanocarriers are also important in developing cancer gene therapies [116]. For example, liposomal nanoparticles have been used to deliver tumor-suppressing genes directly to cancer cells [117]. This targeted approach reduces harm to healthy tissues and increases therapeutic effects, highlighting the value of nanomaterials in precision medicine for cancer treatment [118]. Table 1Applications of nanobiotherapeutic platforms in precision gene and cell therapyTherapeutic applicationNanobiotherapy strategyIntended therapeutic outcomeRefTreatment of inherited disorders (e.g., amyloidosis)Lipid nanoparticles (LNPs) carrying siRNA for gene silencingSuppression of pathogenic protein expression and restoration of normal function[119]Cancer therapy (melanoma, glioblastoma)Polymeric nanoparticles delivering tumor-suppressor or immune-modulating genesTumor growth inhibition and enhanced anti-tumor immunity[120]Blood disorders (hemophilia, thalassemia, sickle cell disease)AAV or lentiviral gene editing in hematopoietic stem cellsCorrection of defective genes and restoration of essential protein synthesis[121]Neurological and muscular diseases (Parkinson’s, Huntington’s, DMD)AAV delivery with ultrasound or microfluidic chips for targeted gene transferFunctional recovery of neurons or muscle fibers via therapeutic gene expression[122]Pulmonary and metabolic diseases (Cystic fibrosis, alpha-1 antitrypsin deficiency)Liposomes or aerosolized gene carriers for localized DNA/RNA deliveryImproved respiratory or hepatic function through gene correction[123]Ocular and cardiovascular diseases (AMD, myocardial infarction)Injectable nanoparticles or engineered exosomes carrying growth factor genesRegeneration of vasculature and improved vision or cardiac perfusion[124]Metabolic and immune disorders (Type 1 diabetes, lysosomal storage diseases)Engineered viral vectors or exosomes delivering enzyme or insulin genesRestoration of insulin secretion or replacement of missing enzymes[125]Genetic DisordersLNP-siRNA systems for gene silencingAlnylam Pharmaceuticals demonstrated effective transthyretin protein reduction in hereditary amyloidosis using Onpattro-like LNP constructs[126]CancerPolymeric nanoparticle-mediated DNA or RNA deliveryUCLA and Ohio State University achieved tumor suppression by co-delivering immune-stimulatory and tumor-suppressor genes[127]Hematologic DiseasesLentiviral or AAV gene correction of hematopoietic stem cellsBluebird Bio restored β-globin synthesis in β-thalassemia and sickle cell disease through ex vivo lentiviral transduction[128]Neurodegenerative & Muscular DisordersAAV-based gene transfer aided by ultrasound or microfluidicsStanford University and Michael J. Fox Foundation targeted dopamine and microdystrophin gene expression in neural and muscle tissues[129]Pulmonary & Hepatic DisordersAerosolized or liposomal gene carriers for localized deliveryVertex and Takeda used liposomal AAV vectors to correct CFTR and α−1 antitrypsin gene defects[130]Ophthalmic & Cardiac RepairInjectable nanoparticles or engineered exosomes delivering VEGF or angiogenic genesHarvard University and Texas Heart Institute induced vascular regeneration in retina and myocardium[131] Applications of nanobiotherapeutic platforms in precision gene and cell therapy One of the main ways nanomaterials reduce off-target effects is by surface modifications that improve cellular specificity [132–135]. When nanomaterial surfaces are functionalized with ligands or peptides, they can selectively bind to specific cell receptors, which directs the nanoparticles to the intended target cells [136]. This targeted process lowers the chance of therapeutic genes affecting non-target cells, thereby reducing off-target effects [137]. In addition, the size and physicochemical properties of nanomaterials help them avoid the immune system and reach the target cells more effectively [138]. Encapsulating therapeutic genes within nanocarriers protects them from degradation and immune detection during circulation [139]. This protection ensures that the therapeutic payload remains intact until it arrives at the target site, which reduces the possibility of off-target interactions [140]. Nanomaterials also provide controlled release systems, which allow a gradual and continuous delivery of therapeutic genes [141]. Such controlled release is important because it prevents sudden increases in gene expression that might otherwise cause off-target effects [142]. By controlling release kinetics, nanomaterials help to maintain a therapeutic concentration at the target site while reducing exposure in non-target tissues [143]. In addition, nanomaterials can cross physiological barriers, such as the blood–brain barrier (BBB), which improves their specificity for particular tissues [144]. This property is very important in gene therapies for diseases of the central nervous system, since off-target effects may cause serious problems [145]. The BBB is a natural barrier that limits the entry of foreign substances, including therapeutic agents, into the brain [146]. Although it is essential for keeping the central nervous system stable, the BBB also creates a major obstacle for delivering gene therapies to treat neurological diseases [147]. Nanomaterials can overcome this obstacle through several mechanisms [148]. One common method is to modify the surface of nanoparticles with ligands or peptides that can attach to receptors on BBB endothelial cells [149]. These modified nanoparticles are able to bind to the receptors, cross the BBB by transcytosis, and deliver therapeutic genes into the brain parenchyma [150]. This strategy increases the specificity of gene delivery and reduces off-target effects in other tissues [151]. The small size of nanomaterials is very important for their ability to pass through the tight junctions of the blood–brain barrier (BBB) [152]. Nanoparticles can use endocytosis and transcytosis pathways to cross the BBB effectively, which makes it possible to deliver therapeutic genes into the brain [153]. This feature is highly useful for treating neurodegenerative diseases and genetic disorders that affect the central nervous system [154]. In addition, nanocarriers help to protect therapeutic genes while they circulate in the body [155]. By encapsulating genes inside nanomaterials, they are protected from enzymatic breakdown and immune system detection, which keeps them safe and functional when they reach the target site in the brain [156]. One of the main functions of liposomal nanoparticles is their capacity to enclose and protect therapeutic genes [150]. The lipid bilayer of liposomes forms a safe environment around the gene cargo, preventing enzymatic breakdown and avoiding immune detection during circulation in the body [157]. This protective role helps ensure the stable and efficient delivery of therapeutic genes to the tumor site [144]. In addition, the surface properties of liposomal nanoparticles can be adjusted to improve their selectivity toward cancer cells [158]. By adding targeting ligands or antibodies, they can specifically recognize and attach to receptors that are highly expressed on the surface of cancer cells [159]. This targeted strategy allows greater build-up of liposomal nanoparticles inside tumor tissue, which improves the therapeutic impact while reducing harm to normal healthy cells [160]. Liposomal nanoparticles can also provide controlled release of therapeutic genes, which allows for longer exposure to cancer cells [161]. This slow release is important because it helps keep an effective number of therapeutic genes in the tumor microenvironment, which improves treatment results [162]. In addition, liposomal nanoparticles are flexible and can deliver more than one therapeutic agent, such as genes together with chemotherapy drugs [163]. Using this combined strategy increases the success of cancer treatment by targeting different parts of tumor growth and development at the same time [164]. Progress in gene-based therapies has also changed personalized medicine, making it possible to design treatments that match the genetic background of each patient [165]. A major benefit of gene-based therapies in personalized medicine is that they can address genetic disorders at their source [166]. Instead of only managing symptoms, these treatments focus on the genetic mutations or problems that cause the disease [167]. This approach provides more effective and lasting results, which fits with the main ideas of personalized medicine [168]. Gene therapies also make it possible to design treatments based on each person’s unique genetic profile [169]. By studying a patient’s genetic data, doctors can find specific markers or mutations that play a role in the development of disease [170]. Tailoring gene therapies to focus on these specific genetic factors can improve treatment effectiveness while reducing possible side effects, creating a more personalized type of patient care [171]. In addition, progress in gene editing tools, especially CRISPR-Cas9, has introduced new chances for accurate genome changes [172]. This progress makes it possible to fix harmful genetic mutations or add therapeutic genes directly into the patient’s genome [173]. Editing genes at the molecular level increases the value of personalized medicine because it addresses the exact genetic causes of diseases [174]. The use of gene-based therapies is not limited to genetic disorders but also extends to cancer treatment [175]. In this case, targeted gene therapies for cancer try to use the unique genetic features of tumor cells, giving a specific approach that avoids unnecessary harm to healthy tissues [176]. Such targeted accuracy is a main feature of personalized medicine, where treatment plans are created based on the genetic and molecular profile of each individual [177]. Precision genome editing techniques Nanomaterials enhance precision genome editing by serving as carriers for gene-editing systems such as CRISPR-Cas9 [178]. Designed mainly as nanoparticles, they possess a large surface area, biocompatibility, and modifiable surfaces [179]. These features enable efficient and targeted genome delivery [180], while their protective and transport functions improve editing outcomes [181]. Common nanomaterials include liposomes, polymers, and inorganic nanoparticles like gold and silica [180]. Liposomes encapsulate genetic material, polymers regulate release, and inorganic nanoparticles provide stability through adjustable surface properties [182]. CRISPR-Cas systems, guided by RNA, allow precise DNA modification to correct or introduce mutations [183–185]. Despite their efficiency and low cost, issues such as off-target activity and ethical concerns remain [186]. Other techniques, including zinc finger nucleases and TALENs, can also induce double-strand breaks [187, 188], yet their design is more complex and less adaptable [189]. Consequently, CRISPR remains the preferred approach while efforts continue to improve its accuracy [190]. Nanomaterials are crucial for carrying CRISPR elements, as they shield genetic material until it reaches target cells [191]. Lipid-based carriers, for instance, form stable structures that prevent degradation and assist cellular entry [192]. Tailored surface features can enhance targeting accuracy and minimize unintended edits [193]. Ongoing work seeks to make these systems safer and more efficient [194]. Surface modification and functionalization help reduce toxicity and improve cell compatibility [195]. Moreover, stimuli-responsive nanomaterials enable precise, localized CRISPR release, advancing safer and more controlled delivery methods [196]. CRISPR technology addresses several issues found in earlier gene-editing tools such as zinc finger nucleases and TALENs by providing a simpler and more adaptable system [197]. Its ability to use easily designed guide RNAs for any DNA sequence increases precision and efficiency, which reduces cost and time in laboratory work. Because of this, CRISPR has become the preferred method for creating targeted genetic modifications in both research and medical fields [198]. Beyond fixing inherited disorders, this technology supports the creation of improved organisms for agriculture, such as disease-resistant crops, and engineered microbes that help produce biofuels more efficiently [199]. It is also an essential tool for studying gene behavior and regulation, helping researchers gain deeper understanding of biological functions [200]. Moreover, its potential in cancer immunotherapy and infectious disease treatment highlights its broad scientific and industrial applications [201]. However, avoiding unintended genetic changes, known as off-target effects, remains a major challenge for CRISPR use [202]. Efforts are ongoing to increase accuracy by improving guide RNA design and modifying Cas enzymes for better target recognition [203]. Computational bioinformatics tools now assist in predicting possible off-target interactions, enabling more effective guide RNA development [204]. Advanced versions of CRISPR that minimize such errors continue to emerge, ensuring higher reliability of the system [205]. Understanding what causes off-target activity also helps scientists design prevention strategies, strengthening the safety and precision of this technology [206]. Through continuous research and refinement, CRISPR is becoming more dependable and practical for future clinical and industrial uses [207]. Meanwhile, delivery of CRISPR components into cells has become another focus of development. Nanomaterial-based carriers are gaining attention for their ability to transport these components safely and efficiently [208]. By modifying surface properties and adding specific functional groups, researchers have reduced toxicity and improved compatibility with living tissues, which enhances their suitability for genome editing [209]. Recent work on stimuli-responsive nanomaterials allows for controlled release of CRISPR elements within specific target cells [210]. This targeted approach enhances editing precision while lowering risks from off-target effects [211]. Such progress in nanotechnology strongly supports the continued advancement of CRISPR-based therapies and applications. Among genome-editing systems, CRISPR remains dominant because it combines simplicity, flexibility, and affordability [212]. Its programmable nature lets scientists modify genes in a wide range of organisms and conditions [213]. While tools like zinc finger nucleases and TALENs are still used, their complex structure and limited adaptability reduce their popularity [214]. In contrast, CRISPR continues to expand its use in many scientific areas, becoming the main tool for precise DNA modification. The applications of precision genome editing are not limited to medical treatment [215]. In agriculture, it helps produce genetically modified crops with improved yield and resistance to harsh environments or pathogens [216]. It also assists in engineering microorganisms that enhance biofuel production, contributing to sustainable energy initiatives [217]. Beyond industry, genome editing gives scientists the means to explore how genes control development and disease, which leads to new insights in cell biology and genetics [218]. The same precision that benefits basic research is now transforming medical practice, especially in cancer immunotherapy and control of viral infections [219]. The ability to alter genetic material accurately opens possibilities for targeted treatments that could redefine future healthcare approaches [220]. As these technologies continue to progress, the influence of genome editing grows across medicine, biotechnology, and environmental science [221]. Another important trend is the integration of nanotechnology with gene-editing systems [222]. Nanomaterials offer unique chemical and physical characteristics that make gene delivery more accurate and efficient, overcoming limits of traditional approaches [223]. As these materials evolve and CRISPR designs improve, the combination of both technologies promises to revolutionize multiple fields, from advanced medical therapies to agricultural innovation [224]. Nanomaterial-based delivery systems Nanomaterial-based delivery systems play an important role in enhancing the targeted delivery of therapeutic agents by using the special properties of nanoparticles, liposomes, and viral vectors. Figure 3 shows the Cellular uptake and intracellular fate of nanoparticles. Because of their very small size, nanoparticles can pass through biological barriers, reach certain cells or tissues, and allow accurate drug delivery [226]. The lipid bilayer structure of liposomes is similar to cell membranes, which helps in cellular uptake and provides controlled release of therapeutic agents [227]. Viral vectors, which are safely modified from viruses, act as highly effective carriers that deliver genetic material to target cells with strong accuracy. Figure 4 presents the use of different analytical methods for studying nano-bio interactions at various levels. Cellular uptake and intracellular fate of nanoparticles. a) Following interaction with the cell membrane, nanoparticles (NPs) are internalized through multiple pathways — including various forms of endocytosis and pinocytosis — depending on their physicochemical properties such as surface chemistry, size, shape, and charge. Uptake may occur through non-specific processes, like membrane wrapping, or specific ligand–receptor interactions on the cell surface. b) After internalization, NPs are typically confined within endosomal vesicles that display distinct structural and biochemical characteristics. For effective delivery, NPs must escape these vesicles before endosomal acidification occurs. Stimuli-responsive NPs, such as ionizable formulations that acquire charge in low-pH environments, facilitate endosomal escape and enable cytosolic release, whereas non-responsive NPs often remain entrapped and are degraded within lysosomes by acidic conditions and proteolytic enzymes. Reprinted from [227], with permission from Springer Nature Nanoparticles overcoming biological barriers in precision medicine. Overview of key biological barriers (inner ring) and precision medicine applications (outer ring) where nanoparticles (NPs) enhance delivery and therapeutic efficacy. Smart NP designs improve intracellular transport, protect cargo from degradation, and support clinical translation. Abbreviations: CAR, chimeric antigen receptor; EGFR, epidermal growth factor receptor; EPR, enhanced permeation and retention; gRNA, guide RNA; RNP, ribonucleoprotein. Reprinted from [227], with permission from Springer Nature Nanoparticles offer several advantages in drug delivery, making them indispensable in the field. Their small size enables efficient cellular uptake, delivering therapeutic agents directly into target cells [229]. The high surface area-to-volume ratio allows for functionalization, tailoring surface properties for specific applications [230]. Additionally, tunable release kinetics ensure controlled and sustained drug release, optimizing therapeutic efficacy [231]. Biocompatible and biodegradable nanoparticle formulations enhance their safety profile, making them ideal carriers for various therapeutic compounds [232]. Table 2 presents an overview of Nanomaterial-Based Delivery Systems, showcasing various advancements and applications in the field. Table 2Used nanomaterial-based on delivery systemsNanomaterial typeCore features & advantagesApplications & research focus/future potentialPolymeric NanoparticlesBiodegradable polymers encapsulating drugs; enable controlled and targeted releaseCancer therapy, vaccines; improving targeting efficiency and developing personalized combination therapy [233]Mesoporous Silica NanoparticlesPorous architecture with high loading capacity and sustained releaseDrug delivery, imaging; controlled-release and bioimaging for theranostic platforms [234]Metallic NanoparticlesGold or silver cores with tunable optical and thermal behaviorCancer and antimicrobial therapy; optimizing biocompatibility and multifunctional theranostics [235]Lipid-based NanoparticlesNatural/synthetic lipid systems enhancing solubility and stabilityGene therapy, vaccines; siRNA and next-generation vaccine delivery [236]Carbon NanotubesCylindrical carbon structures with high loading capacityGene delivery, tissue engineering; improving safety and precision targeting [237]DendrimersBranched macromolecules with modifiable surface groupsImaging, gene therapy; designing multifunctional theranostic platforms [238]Quantum DotsSemiconductor nanocrystals offering strong fluorescenceBiosensing and imaging; improving brightness for image-guided surgery [239]MicellesAmphiphilic aggregates for solubility and sustained drug releaseDrug delivery and imaging; co-delivery of drugs + imaging agents [240–244]Gold NanorodsAnisotropic gold particles with photothermal propertiesCancer therapy and bioimaging; multimodal photothermal strategies [242]SPIONsMagnetic iron oxide nanoparticles acting as MRI contrast agentsDrug delivery, theranostics; MRI-guided hyperthermia and therapy [243]ExosomesNatural vesicles serving as biocompatible carriersVaccines, gene therapy; enhanced drug loading and biological targeting [245]Carbon DotsCarbon-based fluorescent nanostructuresBioimaging, biosensing; multifunctional imaging-drug systems [246]Polymeric HydrogelsCross-linked 3D polymer matrices enabling sustained releaseTissue engineering and cell therapy; personalized degradable drug systems [247] Used nanomaterial-based on delivery systems Engineering precision nanoparticles for drug delivery Chitosan, liposomes, and alginate carriers in drug delivery Chitosan-based nanoparticles are excellent ocular drug carriers due to their biocompatibility and tunable chemistry. Chitosan (CS) is a non-toxic, biodegradable polymer whose free amino and hydroxyl groups can be chemically modified to adjust particle properties [20]. In practice, CS nanoparticles adhere to the eye’s mucosal surface and greatly prolong drug residence time; for example, ophthalmic drugs encapsulated in CS nanoparticles have been shown to significantly increase precorneal residence time [45]. Chitosan NPs can be engineered to carry both hydrophilic and hydrophobic drugs, enabling diverse therapies, and they can be formulated for sustained release of the payload. By adding ligands or exploiting electrostatic interactions, chitosan carriers also support passive and active targeting to ocular tissues, improving treatment of glaucoma, age-related macular degeneration, diabetic retinopathy, and other eye diseases. However, polymeric NPs have challenges: unmodified CS particles can aggregate under physiological conditions, and their capacity for very hydrophobic drugs is relatively limited. These issues can reduce delivery efficiency and must be addressed (for example by surface coatings or hybrid formulations), and current research is actively developing new CS NP designs to overcome them [201–210]. Liposomes are spherical vesicles made of phospholipid bilayers surrounding an aqueous core. They are inherently biocompatible, biodegradable and non-immunogenic, and their bilayer structure naturally carries both water-soluble and lipid-soluble drugs [211]. Highly lipophilic drugs embed in the lipid membrane, whereas hydrophilic drugs reside in the internal aqueous compartment. Liposomes thus offer excellent versatility: they protect drug molecules and allow controlled, sustained release. In ophthalmology, liposomal formulations have been explored to improve delivery of poorly soluble medications (for example, liposomal amphotericin for fungal keratitis or liposomal anti-inflammatory drugs for dry eye) [212]. Moreover, liposomes can be surface-modified (e.g. by attaching targeting ligands) to enable active targeting to specific cells or tissues. On the other hand, liposomal carriers are relatively expensive to manufacture, and they can suffer from physical instability (leakage, fusion or degradation of the lipid bilayer) under storage or physiological conditions. These stability and cost drawbacks motivate ongoing work to optimize liposome design and production methods. Solid or in situ-gelling chitosan implants have been developed to deliver drugs to the eye over long periods. These implantable devices leverage chitosan’s biodegradability and biocompatibility to provide prolonged, controlled release (over weeks to months) of medication, which is ideal for chronic conditions [213–220]. The clear downside is that they require surgical placement. For example, CS-based ocular implants have shown promise in maintaining therapeutic levels for glaucoma or retinoblastoma treatment. Similarly, chitosan-coated prodrug systems have been investigated: chemically linking a drug to chitosan or coating a prodrug particle with CS improves the drug’s solubility and stability and enhances ocular bioavailability. These complex nanostructures allow precise control over release kinetics and can incorporate targeting features, though their design and synthesis are challenging. Overall, chitosan-coated prodrugs represent a powerful strategy for delivering drugs that need improved solubility, stability, and tissue targeting. In oral formulations, alginate (a linear polysaccharide of β-D-mannuronic and α-L-guluronic acids) is widely used in tablets and capsules to deliver proteins, peptides and other labile biomolecules [221–225]. Alginate hydrogels are pH-sensitive: they resist dissolution in the acidic stomach yet swell or dissolve at the higher pH of the intestine, thus targeting drug release to specific gastrointestinal regions. For example, sodium alginate forms a thick gel in contact with gastric acid, creating a protective barrier. Alginate is biocompatible, non-toxic and non-immunogenic, and it can support controlled and sustained release of payloads [226]. A known drawback is that alginate gels can erode before the drug is fully released, potentially causing premature release. To address this, alginate matrices are often combined with enteric coatings or copolymers that prevent early dissolution; the coating acts as a pH-controlled barrier, ensuring the active drug is released at the intended site in the GI tract. Liposomes and alginate represent complementary drug delivery platforms with distinct features. Structurally, liposomes are phospholipid vesicles with adjustable surface charge and complex bilayers, while alginate is a natural linear polymer forming gel networks. Liposomes can encapsulate a wide range of drugs (both hydrophilic and lipophilic) with high loading efficiency and can be actively targeted via ligand attachment [227]. Alginate, by contrast, typically entraps hydrophilic molecules in a hydrogel matrix and delivers them locally (e.g. in the gut or tissue implants). In terms of stability, alginate gels are generally robust in aqueous environments, whereas liposomes often require stabilizers to prevent leakage. Both materials are biocompatible: liposomal formulations are usually well tolerated (though high doses can cause toxicity), and alginate is essentially non-immunogenic and considered very safe. Cost is another key difference: liposomes are relatively costly to manufacture, while alginate – derived from abundant seaweed – is inexpensive and scalable. In summary, liposomes excel in versatility and the ability to incorporate targeting ligands, whereas alginate offers a cost-effective, biodegradable gel matrix ideal for sustained release (e.g. in oral systems or tissue engineering). Each system’s unique strengths address different challenges in drug delivery [228–230]. Applications in CRISPR-based genome editing Applications of CRISPR-based genome editing involve a wide variety of nanomaterials; each used through specific delivery methods to improve precision and efficiency of gene modification [242]. Lipid nanoparticles, applied via encapsulation, have shown enhanced delivery performance and reduced off-target activity in human T cells [243]. In particular, editing the PD-1 gene, an immune checkpoint, produced stronger T cell responses against cancer cells, demonstrating significant potential for progress in cancer immunotherapy [244]. Mesoporous silica nanoparticles, when conjugated with Cas9, provided greater stability and protection of the Cas9 enzyme [245]. This method, when applied to rice plants, successfully targeted the OsSWEET11 gene (a sugar transporter), producing increased drought resistance [246]. Carbon nanotubes, functionalized with guide RNA, displayed improved cellular uptake and efficient targeted delivery in mice [247–252]. By editing the HPRT1 gene (hypoxanthine–guanine phosphoribosyl transferase), this approach corrected a genetic defect, serving as a model for therapeutic applications [253–260]. Polymer nanoparticles, carrying CRISPR components, allowed controlled release and sustained delivery in bacteria [261]. Targeting multidrug resistance genes led to greater sensitivity to antibiotics, offering a potential strategy to overcome antibiotic resistance [261–270]. Exosomes engineered for CRISPR delivery functioned as natural carriers with enhanced biocompatibility and selective targeting [270–273]. In human stem cells, this approach was applied to the β-globin gene (hemoglobin subunit), indicating a possible treatment for sickle cell disease [274–277]. Magnetic nanoparticles, manipulated by an external magnetic field, enabled spatially directed delivery to specific regions of zebrafish embryos. Editing the EGFP gene (fluorescent protein) permitted precise modifications in defined tissues, highlighting opportunities for spatially controlled genome editing [277–283]. Gold nanoparticles, integrated with photothermal ablation and CRISPR, demonstrated a synergistic strategy against cancer cells. In human cancer cells, targeting the EGFR gene (epidermal growth factor receptor) enabled both precise editing and cancer cell destruction, an innovative method reported in reference [7]. Table 3 provides a summary of successful genome editing applications using nanomaterials. Table 3Genome editing applications using nanomaterialsEditing toolNanomaterial carrierTarget gene/pathwayApplication & outcomeRefCRISPR-Cas9Lipid nanoparticlesHBB (β-globin)Delivered Cas9-mRNA and sgRNA to correct β-thalassemia mutation, restoring hemoglobin production[283]CRISPR-Cas9Gold nanoparticlesPCSK9Non-viral delivery led to reduced LDL-cholesterol through gene knockout in liver cells[284]TALENsCarbon nanotubesGFP reporter geneCNTs enhanced DNA uptake efficiency and on-target cleavage, reducing embryonic mosaicism[285]CRISPR-Cas12aMesoporous silica nanoparticlesFT and FLCAchieved simultaneous editing of flowering regulators, altering phenology under controlled delivery[286]CRISPR-Cas9Polymeric nanoparticlesTRAC locusEnabled generation of functional CAR-T cells by integrating CAR construct into T-cell genome[287]CRISPR-Cas9Chitosan nanoparticlesblaTEMFacilitated plasmid-free bacterial genome editing for antibiotic resistance control[288]CRISPR-Cas9Lipid nanoparticlesMECP2Corrected pathogenic mutation linked to Rett syndrome, restoring neuronal transcription balance[289]CRISPR-Cas9Carbon dotsDREB1ATargeted modification improved drought-responsive pathways via non-toxic nanocarrier delivery[290]Base editor (ABE)Lipid nanoparticlesPAHAchieved precise A → G base correction for metabolic defect with minimal off-target activity[291]CRISPR-Cas9Mesoporous silicaBs2Conferred bacterial disease resistance via efficient plasmid-free delivery of editing complex[292]CRISPR-Cas9Cationic liposomeswhite locusImproved germline editing efficiency through stable nucleoprotein encapsulation[293]CRISPR-Cas9PLGA nanoparticlesDMD (dystrophin)Restored dystrophin expression in muscle tissue, improving motor function in disease model[294]CRISPR-Cas9Gold nanorodsVEGFLight-triggered release allowed spatial control of editing, reducing off-target effects[295]CRISPR-Cas9Carbon nanotubesFAD2-1AKnockout increased oleic acid content, demonstrating efficient DNA-free delivery to plant tissue[296]CRISPR-Cas9Graphene oxide nanosheetsBDNF promoterEnhanced neuronal editing efficiency and synaptic plasticity restoration[297]CRISPR-Cas12aChitosan nanoparticlesADH1Increased ethanol yield by multiplex editing of fermentation-related genes[298]CRISPRi (dCas9-KRAB)Magnetic nanoparticlesMYC oncogeneAchieved targeted transcriptional repression for tumor growth inhibition[299]CRISPR-Cas9Silica nanoparticlesALSIntroduced herbicide-tolerant point mutation through precise genome cleavage and repair[300]CRISPR-Cas9Lipid nanoparticlesCEP290Corrected intronic mutation responsible for congenital blindness, restoring photoreceptor function[301]CRISPR-Cas9Gold nanoparticlesInsulin promoterDelivered editing complex to pancreatic cells, restoring insulin synthesis in diabetic model[302]CRISPR-Cas9Lipid-polymer hybrid nanoparticlesCCR5Inserted protective Δ32 deletion to confer HIV resistance in human immune cells[303]CRISPR-Cas9Graphene quantum dotsEGFREnhanced intracellular delivery for tumor-specific knockout and inhibition of cancer proliferation[304]CRISPR-Cas9PEGylated gold nanoparticlesVEGF-ASuppressed angiogenesis through efficient endothelial gene disruption[305]CRISPR-Cas13aLipid nanoparticlesSARS-CoV-2 RNASequence-specific viral RNA degradation achieving > 95% viral load reduction[306]CRISPR-Cas9Polyethylenimine (PEI) nanoparticlesBCL2Triggered apoptosis in leukemia cells via anti-apoptotic gene knockout[307]CRISPR-Cas9Silica-coated magnetic nanoparticlesCFTRCorrected ΔF508 cystic-fibrosis mutation with magnetically guided delivery[308]Base editor (CBE)Lipid nanoparticlesLDLRConverted C → T point mutation restoring receptor function in cholesterol-regulation therapy[309]CRISPR-Cas12aCarbon nanospheresEPSPSConferred glyphosate tolerance through multiplex plant gene modification[310]CRISPR-Cas9PLGA-PEG nanoparticlesPD-1Knockout enhanced antitumor immune response in engineered T cells[311] Genome editing applications using nanomaterials Advances in nanomaterial-based RNAi systems for targeted gene silencing Nanomaterials serve as critical facilitators in RNA interference (RNAi) by providing a stable and protective environment for fragile RNA molecules such as small interfering RNA (siRNA) [312]. Their nanoscale dimensions and tunable surface characteristics allow for efficient encapsulation, protection, and targeted delivery of siRNA into specific cells [313]. This encapsulation shields RNA from enzymatic degradation, enhances stability during circulation, and improves bioavailability at the target site [314]. By enabling precise regulation of disease-associated genes, nanomaterial-mediated RNAi contributes to more effective therapeutic interventions [315]. In addition, nanomaterials significantly influence the pharmacokinetics of RNA molecules by extending their circulation time, preventing premature immune clearance, and promoting enhanced permeability and retention (EPR) effects at diseased tissues [316–318]. The EPR effect allows selective accumulation of nanocarriers at tumor or inflamed sites, thereby raising the local concentration of therapeutic RNA and increasing overall treatment efficacy [319–321]. A major advantage of nanomaterials in RNAi lies in their potential for highly targeted delivery. Through advanced surface modifications, nanoparticles can be functionalized with ligands or antibodies that recognize overexpressed receptors on specific cells [322]. This ligand–receptor interaction ensures selective binding and internalization, directing RNA cargo precisely where needed while reducing off-target effects [323]. Such targeted strategies improve therapeutic outcomes by maximizing siRNA concentration at disease sites, minimizing systemic toxicity, and enhancing overall biocompatibility [324, 325]. Polymeric nanoparticles utilize encapsulation and conjugation techniques, offering high stability, targeted delivery, and controlled release of genetic materials, though they pose risks such as potential toxicity and immune system activation. These nanoparticles are designed for delivering specific genes and mRNAs, showing strong knockdown efficiency and cellular uptake that contribute to tumor suppression and gene silencing. Their applications extend to cancer therapy and genetic diseases, highlighting their role in precision medicine and targeted therapeutic interventions [351]. Lipid nanoparticles employ encapsulation and complexation strategies, providing high biocompatibility and efficient cellular uptake but also facing challenges like potential off-target effects and instability. They target specific genes and mRNAs for gene knockdown and silencing efficiency, making them vital in gene therapy and vaccine development for infectious diseases and genetic disorders [352]. Similarly, carbon nanotubes are used through conjugation and functionalization, allowing high loading capacity and specific targeting; however, issues such as cytotoxicity and agglomeration remain. They are employed for gene silencing and cellular uptake applications in targeted drug delivery and gene therapy, particularly for cancer treatment and neurodegenerative diseases [353]. Gold nanoparticles, by conjugation and functionalization, offer high biocompatibility and ease of modification but may cause immunogenicity and have limited targeting options. Their primary targets are specific genes and mRNAs, promoting gene knockdown and silencing efficiency useful in drug delivery and gene therapy for cancer and inflammatory diseases [354]. Inorganic nanoparticles, utilizing encapsulation and conjugation, deliver high stability and diverse functionalities while facing challenges of toxicity and limited biodegradability. They enhance gene silencing and cellular uptake, enabling imaging and targeted drug delivery for cancer diagnosis and theranostics [355]. Dendrimers and micelles both rely on encapsulation and conjugation, providing high functionality and controlled release. Dendrimers have limitations in in vivo stability and potential cytotoxicity but are efficient for gene knockdown and silencing, making them valuable in drug and gene therapy for cancer and genetic diseases [356]. Micelles, characterized by high biocompatibility and controlled release, suffer from potential stability issues and limited targeting, but they exhibit effective gene knockdown and silencing, making them suitable for drug delivery and gene therapy in cancer and cardiovascular diseases [357]. Liposomes are another well-established platform based on encapsulation and conjugation, known for their biocompatibility though facing stability and targeting constraints; they efficiently achieve gene knockdown and silencing in applications spanning drug and gene therapy for cancer and infectious diseases [358]. Exosomes, naturally derived nanoparticles employing encapsulation, provide efficient cellular uptake and targeted delivery, though limited loading capacity and complex isolation processes restrict their scalability. They effectively silence specific genes and mRNAs, serving as promising carriers in drug and gene therapy for cancer and neurodegenerative diseases [359]. Metal–organic frameworks (MOFs), integrating encapsulation and conjugation, offer tunable porosity and surface chemistry with high biocompatibility, yet there in vivo behavior and off-target effects remain under investigation. MOFs facilitate gene silencing and cellular uptake for drug and gene delivery, playing a potential role in cancer treatment and regenerative medicine [360]. Stimuli-responsive polymers, nanogels, polymeric micelles, nanodiamonds, calcium phosphate nanoparticles, and silica nanoparticles further expand the landscape of nanocarrier systems. Stimuli-responsive polymers, designed for controlled release triggered by pH or temperature changes, present complexity in design and limited in vivo data, but they effectively mediate gene knockdown and silencing for targeted drug delivery and gene therapy in cancer and inflammatory diseases [361]. Nanogels, with their high biocompatibility, controlled release, and loading capacity, face stability and targeting limitations, yet provide efficient gene silencing and delivery capabilities for cancer and genetic disease therapies [362]. Polymeric micelles improve on traditional micelles by offering enhanced stability and biocompatibility but are still challenged by design complexity and targeting limits; they exhibit strong gene knockdown and silencing properties for drug and gene therapy, particularly in cancer and neurodegenerative contexts [363]. Nanodiamonds, characterized by high biocompatibility, unique optical properties, and long circulation times, can aggregate or behave unpredictably in vivo, yet they facilitate gene silencing and cellular uptake, making them suitable for drug delivery, imaging, and gene therapy in cancer and genetic disorders [364]. Calcium phosphate nanoparticles utilize encapsulation and adsorption to achieve biocompatibility and biodegradability with efficient cellular uptake but are constrained by off-target effects and limited loading capacity. They play a key role in gene silencing and vaccine development targeting infectious and genetic diseases [365]. Finally, silica nanoparticles combine encapsulation and conjugation to deliver high biocompatibility and surface modification versatility, though aggregation and uncertain in vivo responses persist. Their ability to mediate gene silencing and uptake supports use in drug delivery, imaging, and gene therapy applications related to cancer treatment and regenerative medicine [366]. Figure 5 illustrates the immunomodulatory effects achieved through nanoparticle mediation and how these contribute to antigen tolerance. Nanoparticle-mediated immunomodulation and induction of antigen tolerance. The upper part of the figure depicts a scenario in which a foreign antigen is taken up by antigen-presenting cells (APCs) together with a pro-inflammatory signal. This dual stimulation primes naïve T cells, leading to activation and proliferation of mature antigen-specific T cells. This response is driven by enhanced antigen presentation via major histocompatibility complexes (MHC), the engagement of co-stimulatory receptors, and secretion of pro-inflammatory cytokines. The lower part illustrates antigen delivery alongside poly(lactic-co-glycolic acid) (PLGA) nanoparticles. As PLGA breaks down into acidic monomers, lactic acid inhibits TAK1, reducing NF-κB phosphorylation and preventing its nuclear translocation. This diminishes T cell responsiveness to pro-inflammatory signals. When sufficient co-stimulation is lacking, antigen presentation does not activate naïve T cells but instead promotes senescence or apoptosis of mature antigen-reactive T cells. The figure highlights key molecules such as IFN-γ (interferon-γ), IL (interleukin), MHC (major histocompatibility complex), TCR (T-cell receptor), and TNF (tumor necrosis factor).Reprinted from [365–369] with permission from Springer Nature Clinical development of nanoparticles for gene delivery Several nanoparticle-based gene therapies have achieved notable milestones in clinical development and regulatory approval, demonstrating the diverse strategies employed for gene delivery and therapeutic efficacy. Onpattro (ALN-TTRsc; NCT02006232), a lipid nanoparticle system targeting transthyretin (TTR), completed Phase III trials with a significant reduction in serum TTR levels and overall improvement in patient outcomes, while maintaining a favorable safety profile with only mild injection site reactions reported. Similarly, Glybera (alipogene tiparvovec; NCT00803319) utilized an adeno-associated viral vector (AAV) to deliver lipoprotein lipase (LPL), becoming the first gene therapy approved in Europe for LPL deficiency. Its success was marked by increased plasma LPL activity and limited side effects, though long-term monitoring continues. Kymriah (tisagenlecleucel; NCT02122952), using a lentiviral vector for CAR T-cell delivery, was approved in the United States as the first CAR T-cell therapy for acute lymphoblastic leukemia. Despite reports of cytokine release syndrome and neurologic toxicities, these were generally manageable with supportive care, and event-free survival outcomes validated its therapeutic promise. Luxturna (voretigene neparvovec-rzyl; NCT00999993), another AAV-based therapy targeting the RPE65 gene, became the first gene therapy approved in the U.S. for Leber congenital amaurosis type 2, showing significant improvement in visual function with only infrequent ocular inflammation from subretinal injection. Emerging therapies continue to expand the gene therapy landscape. AADC-pDC (NCT03709185), an AAV vector targeting aromatic L-amino acid decarboxylase (AADC), is in Phase II clinical evaluation for Parkinson’s disease and has shown early signs of improved motor function while maintaining a well-tolerated safety profile. VYRO-520 (NCT03392333) targets Factor VIII through AAV-mediated delivery and is currently in Phase I/II trials for hemophilia A; early data indicate increased plasma FVIII activity and manageable infusion-related reactions. SG01 (NCT04041524), designed to restore Connexin 26 (GJB2) expression using an AAV vector, is undergoing Phase I evaluation for hearing loss and has demonstrated encouraging improvements in hearing thresholds with minimal adverse effects. In the hematopoietic field, EVI-hPL (NCT03440284) employs lentiviral modification of hematopoietic progenitor stem cells (HPSCs) to enhance engraftment and expansion, showing early feasibility and safety for potential treatment of various blood disorders, with efficacy data pending. Several approved therapies underscore the maturation of gene delivery technologies. Strimvelis (elinogene autocensorapedevec; NCT02244875), employing a retroviral vector to correct ADA deficiency in severe combined immunodeficiency (ADA-SCID), was the first ex vivo gene therapy approved in Europe, though serious adverse events including insertional mutagenesis have been reported. Zolgensma (onasemnogene abeparvovec-xioi; NCT03347586), an AAV-based therapy targeting the SMN1 gene, represents a milestone as the first gene therapy approved in the U.S. for spinal muscular atrophy (SMA) type 1, showing improved event-free survival with promising short-term safety data and ongoing long-term evaluation. Collectively, these clinical and regulatory successes highlight the transformative potential of nanoparticle-mediated and viral-vector-based gene therapies, while emphasizing the continued need for long-term safety monitoring and optimization of delivery platforms to ensure durable, safe, and scalable treatment outcomes for genetic disorders. Lipid-based nanoparticles (LNPs) have emerged as one of the most advanced and clinically validated systems for nucleic acid delivery, playing a central role in the progress of RNA-based therapeutics and gene therapy. Their structural versatility, biocompatibility, and ability to encapsulate and protect fragile genetic materials such as siRNA, mRNA, or plasmid DNA make them suitable for a wide range of therapeutic applications. Several formulations have reached various stages of clinical development, demonstrating both the potential and the challenges associated with nanoparticle-based delivery platforms. One notable example is TKM-080301, developed by Tekmira Pharmaceuticals Corporation (now Arbutus Biopharma). This formulation utilizes lipid nanoparticles for the targeted delivery of siRNA to suppress oncogenic pathways in hepatic metastases (HM). The drug completed Phase 1 clinical trials through intra-arterial (IA) administration (ClinicalTrials.gov Identifier: NCT01437007). Encouraged by its safety profile and initial efficacy, additional clinical trials were initiated. These include Phase 1/2 studies for hepatocellular carcinoma (HCC), which are currently ongoing with active recruitment (NCT02191878). Furthermore, TKM-080301 completed Phase 1/2 trials for neuroendocrine tumors (NET) and adrenocortical carcinoma (ACC) (NCT01262235). These studies collectively demonstrate the adaptability of lipid-based carriers in targeting different malignancies through optimized delivery routes. Another well-recognized formulation is Atu027, developed by Silence Therapeutics GmbH. Atu027 represents a pioneering step in siRNA-based cancer therapy, formulated as a cationic lipid nanoparticle designed to silence protein kinase N3 (PKN3), a gene implicated in tumor metastasis. The compound underwent Phase 1 clinical testing for advanced solid cancers (ASC) via intravenous (IV) administration (NCT00938574). Results from these early trials confirmed the formulation’s tolerability, dose-dependent accumulation in tumor tissues, and preliminary signs of antitumor activity. The success of Atu027 set an important precedent for subsequent generations of lipid nanoparticles in oncological applications. Another significant lipid-based nanocarrier is DOTAP:Chol-FUS1, a cationic liposome formulation developed at the MD Anderson Cancer Center. Unlike polymeric carriers, this system employs DOTAP (dioleoyltrimethylammonium propane) and cholesterol to encapsulate the FUS1 tumor suppressor gene. It was designed for the treatment of non-small cell lung cancer (NSCLC) and underwent Phase 1 clinical testing through intravenous administration (NCT00059605). The trials demonstrated gene transfer feasibility, limited toxicity, and potential tumor growth suppression, supporting further investigation into cationic lipid formulations as gene delivery platforms. Another innovative candidate is DCR-MYC, developed by Dicerna Pharmaceuticals. This LNP-based siRNA therapeutic targets the oncogene MYC, which regulates multiple cellular processes including proliferation and apoptosis. DCR-MYC has been evaluated in Phase 1 and Phase 1/2 clinical trials for a range of cancers including solid tumors (ST), multiple myeloma (MM), non-Hodgkin’s lymphoma (NHL), and hepatocellular carcinoma (HCC) (NCT02314052). The use of lipid nanoparticles allows efficient intracellular delivery and gene silencing, showing the continued promise of LNP systems in tackling both hematologic and solid malignancies. Beyond lipid systems, PLGA-based nanoparticles have also found applications in gene therapy. A key example is siG12D LODER, developed by Silenseed, which uses biodegradable poly(lactic-co-glycolic acid) matrices to deliver siRNA against the KRAS G12D mutation prevalent in pancreatic cancer (PC). Administered locally to the tumor site, this formulation is currently in Phase 2 clinical trials (NCT01676259). Its slow and sustained release profile enhances siRNA stability and prolongs therapeutic activity, addressing the challenge of short RNA half-life in vivo. Ensuring safe, responsible, and equitable gene therapy Nanomaterials in gene therapy pose numerous scientific, regulatory, and ethical challenges that must be systematically addressed to ensure safety and efficacy [370–375]. One of the main concerns is the potential toxicity of certain nanomaterials [376]. Due to their distinctive physicochemical features—such as high surface area, charge, and reactivity—nanoparticles can interact unpredictably with biological systems, leading to cytotoxic or immunogenic reactions [377]. Consequently, understanding their toxicological profiles is essential for minimizing harm and ensuring clinical safety [378]. Another persistent obstacle lies in efficient and targeted delivery to specific cells [378]. Achieving precision while limiting off-target effects requires highly engineered delivery systems capable of traversing biological barriers [379]. These systems must retain their function under physiological conditions and reach the intended tissues effectively, which remains a crucial challenge in nanomedicine [380]. Additionally, long-term stability and tissue accumulation of nanomaterials are significant issues [381]. Investigating biodistribution, metabolism, and clearance mechanisms helps prevent undesirable consequences associated with chronic exposure [382]. From a governance standpoint, regulatory frameworks play a decisive role in managing nanomaterial applications in gene therapy [383]. Agencies like the FDA and EMA have established structures to evaluate safety, quality, and therapeutic performance [384]. Before initiating human trials, researchers must provide extensive data about physicochemical properties, toxicity, and manufacturing processes [385]. Such preclinical requirements ensure that potential risks and benefits are fully reviewed before clinical testing begins [386]. Furthermore, ethical scrutiny forms an integral part of this process [387]. Human studies must undergo strict ethical assessments to safeguard participants’ rights and welfare [388]. Informed consent, privacy assurance, and transparency are non-negotiable principles [389]. Post-marketing surveillance further ensures ongoing safety assessment, enabling prompt identification of emerging risks even after commercialization [390]. A key scientific challenge is minimizing off-target effects in nanomaterial-based gene therapy [391]. Strategies to address this include designing nanocarriers with enhanced specificity [391]. Functionalizing nanoparticle surfaces improves selective binding to target cells and limits nonspecific interactions [392]. Advanced imaging technologies enable real-time monitoring of biodistribution and pharmacokinetics, providing data for optimizing precision [393, 394]. Incorporating smart targeting systems such as ligands or antibodies further increases selectivity by binding specific cellular receptors [395, 396]. Adjusting size and morphology of nanomaterials also affects circulation time and cellular uptake [397], improving delivery while decreasing unintended interactions [398]. Extensive preclinical testing—both in vitro and in vivo—remains critical for detecting off-target events early and ensuring translational safety [399, 400]. To manage immunogenic responses, researchers must understand how nanomaterials interact with immune components [401]. Designing immunomodulatory nanomaterials helps minimize inflammation and enhance immune tolerance [402]. Surface modifications, particularly PEGylation, effectively reduce immune recognition and prolong systemic circulation [403–411]. Selecting biocompatible and biodegradable materials such as lipids or natural polymers lowers immunotoxicity [404, 405]. Rigorous immunotoxicity evaluations are necessary to identify cytokine responses, immune cell activation, or imbalance [406, 407]. Implementing immune evasion strategies—for instance, molecular camouflage or integration with immunosuppressants—further reduces recognition and immune clearance [408]. Ethical conduct in nanomaterial-based gene therapy relies on foundational principles [409]. Informed consent ensures participants are fully aware of potential risks and expected benefits [410]. Maintaining transparent communication is vital for participant trust and autonomy [411]. Protection of privacy and data security is another pillar; anonymization and strict confidentiality measures are necessary to protect sensitive information [412, 413]. Equitable access represents a broader ethical concern [312]. All populations should benefit from gene therapy without discrimination or socioeconomic exclusion [316]. This requires addressing affordability, accessibility, and inclusivity in clinical research [300]. Scientists must also examine the societal implications of gene therapy, such as genetic discrimination or social inequality [310, 326]. Ethical frameworks should guide every decision, promoting justice and minimizing harm [327–340]. Continuous ethical oversight—from early development to post-approval monitoring—is essential to sustain accountability [340–342]. Institutional review boards and regulatory bodies must ensure adherence to these principles throughout research and application [304]. Given the rapid progress of nanotechnology, adaptive regulatory systems are required [306]. Collaborative networks involving regulators, scientists, industrial partners, and ethicists support real-time knowledge sharing and dynamic risk assessment [343–348]. Frequent updates to guidelines keep regulations aligned with new scientific evidence and innovations [348–350]. Special regulatory pathways may accelerate evaluation and approval of nanomaterial-based therapies while ensuring safety [301]. Recognizing both the unique potential and risks of nanotechnology allows for tailored frameworks that balance innovation with patient protection [314]. Continuous communication between regulators and industry enhances compliance and coordinated responses to emerging issues [211, 284]. The use of adaptive licensing strategies, including conditional approvals and ongoing post-market studies, allows regulators to accommodate rapid technological shifts [212]. Collecting real-world data refines risk–benefit analyses and updates decision-making in line with scientific progress [216]. International cooperation is indispensable for harmonizing regulations and guaranteeing global safety standards [217]. Joint frameworks allow authorities across regions to align testing protocols, share best practices, and manage cross-border risks [218]. Establishing international task forces focused on nanotechnology in gene therapy fosters collaborative policy development [219, 220]. Conferences and workshops in nanomedicine provide further platforms for cooperation and exchange of emerging insights [221, 222]. A shared terminology and classification system for nanomaterials is vital for consistent communication across scientific, industrial, and regulatory communities [223, 224]. Transparent data sharing and open access to safety and efficacy results strengthen evidence-based decision-making [225]. Developing international repositories containing nanomaterial profiles enhances reproducibility and helps create uniform standards [226]. Effective collaboration between industry and regulators streamlines the approval process [227]. Constructive, early engagement promotes clarity on study expectations and reduces approval delays [228–231]. Participation in regulatory pilot projects for nanomaterial applications provides valuable testing grounds for improving methodologies [150, 232]. Sound data generation and transparency underpin public and regulatory trust [233–235]. Comprehensive preclinical and clinical datasets on safety, quality, and efficacy are essential for evidence-based review [234]. A risk-based regulatory approach prioritizes oversight according to the potential impact of each component or process [236, 237]. This enables efficient resource allocation while maintaining safety rigor. Furthermore, the establishment of international ethical standards requires input from diverse stakeholders, including ethicists, policymakers, and researchers [238, 239]. Global organizations such as WHO and UNESCO play central roles in promoting coordinated frameworks for ethical nanomedicine [301]. Specialized expert panels can address nuances of ethical governance in nanomaterial-based gene therapy [312]. Active public engagement is another cornerstone of ethical governance [300]. Since gene therapy intersects with cultural, social, and moral dimensions, including public perspectives ensures that norms reflect collective values [316]. Open consultation processes enhance transparency and democratic legitimacy in rule-making [317]. Because scientific and societal conditions evolve quickly, periodic review of ethical guidelines guarantees ongoing relevance [319, 332]. International bioethics collaborations contribute expertise and consistency in global standards [330]. Aligning national regulations with established international conventions facilitates a unified and responsible approach to nanomaterial applications in gene therapy [302]. Future directions Nanomaterials are redefining the landscape of gene therapy through innovative approaches that merge materials science with molecular medicine. Instead of relying solely on traditional delivery systems, researchers now employ diverse nanoparticles—such as liposomes, polymeric carriers, and inorganic nanostructures—to transport therapeutic genes directly into target cells. Liposomes, valued for their biocompatibility, can encapsulate both water-soluble and fat-soluble genetic materials. Polymeric nanoparticles stand out for their customizable design and precise control of gene release, while inorganic materials like gold and silica offer unique surface chemistry for fine-tuned targeting and controlled delivery. Modern research emphasizes engineering nanomaterials that are safer, more stable, and more responsive to biological environments. A growing focus is on “smart” systems—materials that react to pH, enzymes, or temperature—releasing genes only under specific physiological conditions. This responsiveness improves treatment accuracy and minimizes side effects. Another key trend is the rise of multifunctional nanoplatforms capable of both delivering therapeutic genes and providing diagnostic imaging, helping clinicians track the therapy’s progress in real time. The next generation of nanomaterials aims to overcome major delivery obstacles. Efforts include developing carriers that selectively accumulate in target tissues or cross biological barriers for oral gene delivery—an approach that could simplify administration and enhance patient compliance. Adjusting factors such as particle size, charge, and surface coating further improves pharmacokinetics and reduces immune reactions. Emerging technologies such as artificial intelligence and machine learning are expected to guide the rational design of future nanocarriers, optimizing their shape, composition, and release dynamics. As these technologies mature, personalized nanomedicine where therapies are tailored to an individual’s genetic profile will likely become routine. Altogether, the evolution of nanomaterials signals a fundamental shift toward safer, smarter, and more individualized gene therapy strategies poised to transform modern biomedical treatment. Acknowledgements The authors appreciate the constructive comments from the anonymous reviewers, which significantly improved the quality of this paper. Author contributions MJ, KZ, ZW, MG, SS, JH, HX, HX, ZB, ZJ, CZ, JH, and RW searching, writing- original draft preparation. All authors approved the final version of the manuscript. Funding This research was supported by Health Youth Talent Project of Shanghai Municipal Health Commission (No.2022YQ028), Young Elite Scientists Sponsorship Program by BATSA (BYESS2023244) and Beijing Institute of Technology Research Fund Program for Young Scholars. Data availability Not applicable. Declarations Ethics approval and consent to participate Not applicable. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Mingyang Jiang, Ke Zhang and Zheng Wang are co-first authors. Contributor Information Zhenqi Jiang, Email: jiangzhenqi@bit.edu.cn. Chengcheng Zhang, Email: 18117022797@163.com. James HP. Hui, Email: doshuij@nus.edu.sg Ruqiong Wei, Email: weiruqiongxibanya@163.com. References Associated Data Data Availability Statement Not applicable.